Skip to main content

Table 4 Postoperative metastatic patterns of patients with stage III colon cancer after curative treatment

From: Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience

Metastatic parameters Standard XELOX
(n = 126, %)
Modified XELOX
(n = 84, %)
Unfinished XELOX
(n = 120, %)
P value 1 P value 2
Postoperative metastasis     0.861 0.046
 Present 23 (18.3) 14 (16.7) 35 (29.2)   
 Absent 103 (81.7) 70 (83.3) 85 (70.8)   
Liver metastasis     0.821 0.798
 Present 8 (6.3) 6 (7.1) 11 (9.2)   
 Absent 118 (93.7) 78 (92.9) 109 (90.8)   
Lung metastasis     0.570 0.739
 Present 9 (7.1) 4 (4.8) 7 (5.8)   
 Absent 117 (92.9) 80 (95.2) 113 (94.2)   
Abdominopelvic metastasis     0.735 0.017
 Present 4 (3.2) 2 (2.4) 14 (11.7)   
 Absent 122 (96.8) 82 (97.6) 106 (88.3)   
  1. XELOX oxaliplatin and capecitabine regimen
  2. P value 1 is the result of comparing the standard XELOX regimen group with the modified XELOX regimen group. P value 2 is the result of comparing the unfinished XELOX regimen with the modified XELOX regimen group